Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- CLNE +19.2%, OPGN +15.4%, ADVM +12.7%, YELP +12.6%, SUNW +10.7%, VRNS +9.6%, DXPE +8.9%, BBSI +8.6%,COTV +7.7%, DHT +7.7%, NH +7.3%, YRD +7.3%, HCHC +7%, WATT +6.7%, (also announces $20 mln private placement), RL +6.6%, INFI +5.6%, CDXS +5.3%
- LITE +4.9%, HALO +4.8%, RYI +4.4%, JD +4.1%, XONE +3.7%, CEL +3.7%, OXLC +3.4%, HLIT +3.3%, CRME +3.2%, (also XYDALBA has been approved by the EMA for administration as a single, 30 minute, 1500mg infusion), AG +3.1%, ICLD+2.9%, CPRX +2.8%, ARMK +2.7%, PUK +2.5%, EDIT +2.4%, TCS +2.4%
- TAHO +1.9%, OTIV +1.8%, WAGE +1.7%, RBCN +1.7%, ICL +1.5%, PTLA +1.1%, AEZS +1.1%, IEC +1%
Select metals/mining stocks trading higher: EGO +4.9%, MUX +4.4%, BTG +4%, GFI +3.9%, KGC +3.9%, SWC +3.3%,CDE +3.2%, HL +3.1%, FCX +3%, SLV +2.9%, ABX +2.8%, GDX +2.7%, GOLD +2.6%, AU +2.6%, GG +2.5%, AUY +2.3%,NEM +2.2%, MT +1.6%, BHP +1.5%, IAG +1.2%, GLD +1.1%
Other news:
Other news:
- APRI +27.9% (announces that Ferring Pharmaceuticals, the Company's new partner in Germany, has received the German marketing authorization for Vitaros)
- VTVT +15.5% (announces 'positive' topline results from a Phase 2b study of TTP399; achieves primary endpoint)
- CBMX +12.3% (announces that Universal Diagnostic Labs will market and distribute its chromosomal microarray miscarriage analysis test in both Northern and Southern California)
- VSAR +11.5% (Versartis and Teijin LImited enter into an exclusive license and supply agreement for the development and commercialization of somavaratan in Japan; will receive an upfront payment of $40 million )
- PLX +11.1% (announces additional 'positive' data from its phase I/II clinical trial of PRX-102 for the treatment of Fabry disease)
- OCN +7.9% (S&P raised its ranking on Ocwen Loan Servicing LLC Commercial Servicer, Ocwen Loan Servicing LLC Residential Master Servicer to Average)
- KTOV +6.8% (receives US patent for its lead drug candidate KIT-302)
- TOPS +5.9% (announces delivery of sixth newbuilding vessel & completion of six-vessel newbuilding program)
- JBLU +1.6% (reports July 2016 prelim traffic)
Analyst comments:
- ZIOP +6.4% (upgraded to Market Perform from Underperform at Wells Fargo
- SSL +3.1% (upgraded to Overweight from Equal Weight at Morgan Stanley)
- ASPS +2.7% (upgraded to Buy at Compass Point)
- PHG +2.2% (upgraded to Buy from Neutral at UBS)